139 related articles for article (PubMed ID: 20535124)
1. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A
J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
3. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.
Firoz EF; Warycha M; Zakrzewski J; Pollens D; Wang G; Shapiro R; Berman R; Pavlick A; Manga P; Ostrer H; Celebi JT; Kamino H; Darvishian F; Rolnitzky L; Goldberg JD; Osman I; Polsky D
Clin Cancer Res; 2009 Apr; 15(7):2573-80. PubMed ID: 19318491
[TBL] [Abstract][Full Text] [Related]
4. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
5. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
6. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
[TBL] [Abstract][Full Text] [Related]
7. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
8. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
9. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
11. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
12. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
13. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
[TBL] [Abstract][Full Text] [Related]
14. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
16. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
17. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
18. Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults.
Onel KB; Huo D; Hastings D; Fryer-Biggs J; Crow MK; Onel K
Lupus; 2009 Jan; 18(1):61-6. PubMed ID: 19074170
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
20. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]